Michael Gregor
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Fürstenau M, Thus Y, Robrecht S, Mellink C, van der Kevie-Kersemaekers A, Dubois J, von Tresckow J, Patz M, Gregor M, Thornton P, Staber P, Tadmor T, Levin M, da Cunha-Bang C, Schneider C, Poulsen C, Illmer T, Schöttker B, Janssens A, Christiansen I, Noesslinger T, Baumann M, Hebart H, Gaska T, Regelink J, Dompeling E, Lindstrom V, Juliusson G, Widmer A, Goede J, Goldschmidt N, Simon F, De Silva N, Fink A, Fischer K, Wendtner C, Ritgen M, Brüggemann M, Tausch E, Spaargaren M, Eldering E, Stilgenbauer S, Niemann C, Hallek M, Eichhorst B, Kreuzer K, Kater A. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations. Blood 2023
May 12, 2023High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
May 12, 2023Blood 2023
Fürstenau Moritz, Thus Yvonne J, Robrecht Sandra, Mellink Clemens H M, van der Kevie-Kersemaekers Anne-Marie F, Dubois Julie, von Tresckow Julia, Patz Michaela, Gregor Michael, Thornton Patrick, Staber Philipp B, Tadmor Tamar, Levin Mark-David, da Cunha-Bang Caspar, Schneider Christof, Poulsen Christian Bjørn, Illmer Thomas, Schöttker Björn, Janssens Ann, Christiansen Ilse, Noesslinger Thomas, Baumann Michael, Hebart Holger, Gaska Tobias, Regelink Josien, Dompeling Ellen C, Lindstrom Vesa, Juliusson Gunnar, Widmer Anouk Andrea, Goede Jeroen, Goldschmidt Neta, Simon Florian, De Silva Nisha, Fink Anna Maria, Fischer Kirsten, Wendtner Clemens-Martin, Ritgen Matthias, Brüggemann Monika, Tausch Eugen, Spaargaren Marcel, Eldering Eric, Stilgenbauer Stephan, Niemann Carsten Utoft, Hallek Michael, Eichhorst Barbara, Kreuzer Karl-Anton, Kater Arnon P
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Eichhorst B, Niemann C, Kater A, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, Staber P, Tadmor T, Lindstrom V, da Cunha-Bang C, Schneider C, Poulsen C, Illmer T, Schöttker B, Noesslinger T, Janssens A, Christiansen I, Baumann M, Frederiksen H, Klift M, Jäger U, Leys M, Hoogendoorn M, Lotfi K, Hebart H, Gaska T, Koene H, Enggaard L, Goede J, Regelink J, Widmer A, Simon F, De Silva N, Fink A, Bahlo J, Fischer K, Wendtner C, Kreuzer K, Ritgen M, Brüggemann M, Tausch E, Levin M, van Oers M, Geisler C, Stilgenbauer S, Hallek M, GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. N Engl J Med 2023; 388:1739-1754.
May 11, 2023First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
May 11, 2023N Engl J Med 2023; 388:1739-1754
Eichhorst Barbara, Niemann Carsten Utoft, Kater Arnon P, Fürstenau Moritz, von Tresckow Julia, Zhang Can, Robrecht Sandra, Gregor Michael, Juliusson Gunnar, Thornton Patrick, Staber Philipp B, Tadmor Tamar, Lindstrom Vesa, da Cunha-Bang Caspar, Schneider Christof, Poulsen Christian Bjørn, Illmer Thomas, Schöttker Björn, Noesslinger Thomas, Janssens Ann, Christiansen Ilse, Baumann Michael, Frederiksen Henrik, Klift Marjolein van der, Jäger Ulrich, Leys Maria B L, Hoogendoorn Mels, Lotfi Kourosh, Hebart Holger, Gaska Tobias, Koene Harry, Enggaard Lisbeth, Goede Jereon, Regelink Josien, Widmer Anouk Andrea, Simon Florian, De Silva Nisha, Fink Anna Maria, Bahlo Jasmin, Fischer Kirsten, Wendtner Clemens-Martin, Kreuzer Karl A, Ritgen Matthias, Brüggemann Monika, Tausch Eugen, Levin Mark-David, van Oers Marinus, Geisler Christian, Stilgenbauer Stephan, Hallek Michael, GCLLSG, the HOVON and Nordic CLL Study Groups, the SAKK, the Israeli CLL Association, and Cancer Trials Ireland
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
Ossenkoppele G, Pabst T, Oosterveld M, Obbergh F, Nijziel M, Moors I, Kooy M, Maertens J, Loosdrecht A, Legdeur M, Poel M, Sinnige H, Spertini O, Norden Y, Stussi G, Westerweel P, Weerdt O, Vellenga E, Vekemans M, Velden W, Tick L, Terpstra W, Lammeren-Venema D, Kuball J, Deeren D, Chalandon Y, Brouwer R, Breems D, Borne P, Biemond B, Bargetzi M, Manz M, Löwenberg B, Efthymiou A, Gjertsen B, Graux C, Klift M, Klein S, Jongen-Lavrencic M, Jie A, Jaspers A, Hoogendoorn M, Hess U, Heim D, Gregor M, Janssen J. Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers (Basel) 2021; 13
Feb 7, 2021Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
Feb 7, 2021Cancers (Basel) 2021; 13
Ossenkoppele Gert, Pabst Thomas, Oosterveld Margriet, Obbergh Florence van, Nijziel Marten, Moors Ine, Kooy Marinus van Marwijk, Maertens Johan, Loosdrecht Arjan van de, Legdeur Marie-Cecile, Poel Marjolein van der, Sinnige Harm, Spertini Olivier, Norden Yvette van, Stussi Georg, Westerweel Peter, Weerdt Okke de, Vellenga Edo, Vekemans Marie-Christiane, Velden Walter van der, Tick Lidwine, Terpstra Wim, Lammeren-Venema Danielle van, Kuball Jurgen, Deeren Dries, Chalandon Yves, Brouwer Rolf, Breems Dimitri, Borne Peter von dem, Biemond Bart, Bargetzi Mario, Manz Markus, Löwenberg Bob, Efthymiou Anna, Gjertsen Bjørn-Tore, Graux Carlos, Klift Marjolein van der, Klein Saskia, Jongen-Lavrencic Mojca, Jie Asiong, Jaspers Aurelie, Hoogendoorn Mels, Hess Urs, Heim Dominik, Gregor Michael, Janssen Jeroen
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Ossenkoppele G, Porkka K, Cornelissen J, Kuball J, Fischer T, Legdeur M, Hoogendoorn M, Breems D, Moors I, van Lammeren-Venema D, Silzle T, Juliusson G, Meyer P, Floisand Y, Manz M, van Elssen C, Valk P, Cloos J, Passweg J, Huls G, Janssen J, Gjertsen B, Höglund M, Gregor M, Veelken H, van Marwijk Kooy M, Jongen-Lavrencic M, Tick L, Griskevicius L, Vellenga E, Spertini O, Biemond B, Gradowska P, Maertens J, Pabst T, Vekemans M, van der Velden W, Westerweel P, Gadisseur A, Klein S, Bargetzi M, van Esser J, de Weerdt O, Deeren D, Graux C, Michaux L, Beverloo B, Löwenberg B. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood Adv 2021; 5:1110-1121.
Jan 23, 2021Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Jan 23, 2021Blood Adv 2021; 5:1110-1121
Ossenkoppele Gert J, Porkka Kimmo, Cornelissen Jan, Kuball Juergen, Fischer Thomas, Legdeur Marie-Cecile J C, Hoogendoorn Mels, Breems Dimitri A, Moors Ine, van Lammeren-Venema Daniëlle, Silzle Tobias, Juliusson Gunnar, Meyer Peter, Floisand Yngvar, Manz Markus G, van Elssen Catharina H M J, Valk Peter J M, Cloos Jacqueline, Passweg Jakob, Huls Gerwin, Janssen Jeroen J W M, Gjertsen Bjorn T, Höglund Martin, Gregor Michael, Veelken Hendrik, van Marwijk Kooy Marinus, Jongen-Lavrencic Mojca, Tick Lidwine W, Griskevicius Laimonas, Vellenga Edo, Spertini Olivier, Biemond Bart J, Gradowska Patrycja, Maertens Johan, Pabst Thomas, Vekemans Marie-Christiane, van der Velden Walter J F M, Westerweel Peter E, Gadisseur Alain, Klein Saskia K, Bargetzi Mario, van Esser Joost W J, de Weerdt Okke, Deeren Dries, Graux Carlos, Michaux Lucienne, Beverloo Berna, Löwenberg Bob
Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013
Schnegg-Kaufmann A, Bonadies N, Arndt V, Stussi G, Passweg J, Chalandon Y, Spertini O, Hess U, Bargetzi M, Efthymiou A, Gregor M, Manz M, Rovó A, Baldomero H, Feller A, NICER Working Group. Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013. Cancer Epidemiol 2017; 52:55-62.
Dec 7, 2017Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013
Dec 7, 2017Cancer Epidemiol 2017; 52:55-62
Schnegg-Kaufmann Annatina, Bonadies Nicolas, Arndt Volker, Stussi Georg, Passweg Jakob R, Chalandon Yves, Spertini Olivier, Hess Urs, Bargetzi Mario, Efthymiou Anna, Gregor Michael, Manz Markus G, Rovó Alicia, Baldomero Helen, Feller Anita, NICER Working Group
Reduced aspirin responsiveness as assessed by impedance aggregometry is not associated with adverse outcome after cardiac surgery in a small low-risk cohort
Bolliger D, Filipovic M, Matt P, Tanaka K, Gregor M, Zenklusen U, Seeberger M, Lurati Buse G. Reduced aspirin responsiveness as assessed by impedance aggregometry is not associated with adverse outcome after cardiac surgery in a small low-risk cohort. Platelets 2015:1-8.
Sep 14, 2015Reduced aspirin responsiveness as assessed by impedance aggregometry is not associated with adverse outcome after cardiac surgery in a small low-risk cohort
Sep 14, 2015Platelets 2015:1-8
Bolliger Daniel, Filipovic Miodrag, Matt Peter, Tanaka Kenichi A, Gregor Michael, Zenklusen Urs, Seeberger Manfred D, Lurati Buse Giovanna
Transfusion of allogeneic blood products in proximal aortic surgery with hypothermic circulatory arrest: effect of thromboelastometry-guided transfusion management
Fassl J, Matt P, Eckstein F, Filipovic M, Gregor M, Zenklusen U, Seeberger M, Bolliger D. Transfusion of allogeneic blood products in proximal aortic surgery with hypothermic circulatory arrest: effect of thromboelastometry-guided transfusion management. J Cardiothorac Vasc Anesth 2013; 27:1181-8.
Aug 17, 2013Transfusion of allogeneic blood products in proximal aortic surgery with hypothermic circulatory arrest: effect of thromboelastometry-guided transfusion management
Aug 17, 2013J Cardiothorac Vasc Anesth 2013; 27:1181-8
Fassl Jens, Matt Peter, Eckstein Friedrich, Filipovic Miodrag, Gregor Michael, Zenklusen Urs, Seeberger Manfred D, Bolliger Daniel
Pre-analytical effects of pneumatic tube transport on impedance platelet aggregometry
Bolliger D, Seeberger M, Tanaka K, Dell-Kuster S, Gregor M, Zenklusen U, Grapow M, Tsakiris D, Filipovic M. Pre-analytical effects of pneumatic tube transport on impedance platelet aggregometry. Platelets 2009; 20:458-65.
Nov 1, 2009Pre-analytical effects of pneumatic tube transport on impedance platelet aggregometry
Nov 1, 2009Platelets 2009; 20:458-65
Bolliger Daniel, Seeberger Manfred D, Tanaka Kenichi A, Dell-Kuster Salome, Gregor Michael, Zenklusen Urs, Grapow Martin, Tsakiris Dimitrios A, Filipovic Miodrag
Polysomy 8 defines a clinico-cytogenetic entity representing a subset of myeloid hematologic malignancies associated with a poor prognosis: report on a cohort of 12 patients and review of 105 published cases
Beyer V, van Melle G, Schmidt P, Schanz U, Laurencet F, Chapuis B, Hess U, Hitz F, Gregor M, Pugin P, Tobler A, Solenthaler M, Bougeon-Mamin S, Cabrol C, Parlier V, Mühlematter D, Jotterand M. Polysomy 8 defines a clinico-cytogenetic entity representing a subset of myeloid hematologic malignancies associated with a poor prognosis: report on a cohort of 12 patients and review of 105 published cases. Cancer genetics and cytogenetics 2005; 160:97-119.
Jul 15, 2005Polysomy 8 defines a clinico-cytogenetic entity representing a subset of myeloid hematologic malignancies associated with a poor prognosis: report on a cohort of 12 patients and review of 105 published cases
Jul 15, 2005Cancer genetics and cytogenetics 2005; 160:97-119
Beyer Valérie, van Melle Guy, Schmidt Pierre-Michel, Schanz Urs, Laurencet France, Chapuis Bernard, Hess Urs, Hitz Felicitas, Gregor Michael, Pugin Paul, Tobler Andreas, Solenthaler Max, Bougeon-Mamin Sandrine, Cabrol Christine, Parlier Valérie, Mühlematter Dominique, Jotterand Martine